



HHS Public Access

Author manuscript

Bioorg Med Chem. Author manuscript; available in PMC 2019 May 15.

Published in final edited form as:

Bioorg Med Chem. 2018 May 15; 26(9): 2354–2364. doi:10.1016/j.bmc.2018.03.033.

Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of aryl-naphthalene lignan lactones

John L. Woodard^{†,a}, Andrew C. Huntsman^{†,a}, Pratiq A. Patel^a, Hee-Byung Chai^a, Ragu Kanagasabai^b, Soumendrakrishna Karmahapatra^b, Alexandria N. Young^c, Yulin Ren^a, Malcolm S. Cole^a, Denisse Herrera^c, Jack C. Yalowich^b, A. Douglas Kinghorn^a, Joanna E. Burdette^c, and James R. Fuchs^{*,a}

^aDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus OH 43210

^bDivision of Pharmacology, College of Pharmacy, The Ohio State University, Columbus OH 43210

^cDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois-Chicago, Chicago IL 60612

Abstract


A series of aryl-naphthalene lignan lactones based on the structure of the phyllanthusmins, a class of potent natural products possessing diphyllin as the aglycone, has been synthesized and screened for activity against multiple cancer cell lines. SAR exploration was performed on both the carbohydrate and lactone moieties of this structural class. These studies have revealed the importance of functionalization of the carbohydrate hydroxy groups with both acetylated and methylated analogues showing increased potency relative to those with unsubstituted sugar moieties. In addition, the requirement for the presence and position of the C-ring lactone has been demonstrated through reduction and selective re-oxidation of the lactone ring. The most potent compound in this study displayed an IC₅₀ value of 18 nM in an HT-29 assay with several others ranging from 50 to 200 nM. In an effort to elucidate their potential mechanism(s) of action, the DNA topoisomerase IIa inhibitory activity of the most potent compounds was examined based on previous reports of structurally similar compounds, but does not appear to contribute significantly to their antiproliferative effects.

Graphical Abstract

*Corresponding author at present address: 500 W. 12th Avenue, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States., fuchs.42@osu.edu.

[†]These authors contributed equally.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1. Introduction

The genus *Phyllanthus* has historically been a rich source of natural products possessing diverse chemical structures and biological activities.¹ Building in part upon this diversity, a recent effort to identify novel compounds with cytotoxic activity from *Phyllanthus poilanei* by Kinghorn and coworkers led to the isolation of two new natural products, phyllanthusmins D and E (Fig. 1),² along with the previously reported phyllanthusmins A–C.³ The isolated phyllanthusmins displayed promising potent antiproliferative activity against various cancer cell lines, with phyllanthusmin D displaying the most potent activity with an IC₅₀ value of 0.17 μM against HT-29 colon carcinoma cells and a semisynthetic analogue, 2''-acetyl-phyllanthusmin D, also exhibiting similarly potent activity in the same cell line (IC₅₀ = 0.11 μM).²

From a structural perspective, the phyllanthusmins represent a subset of the arylnaphthalene lignan lactone class of natural products (Fig. 1A). Phyllanthusmins B–E are diphyllin glycosides possessing substituted arabinose units linked via a glycosidic bond to the C7 phenol of diphyllin, the aglycone portion of the molecule and a natural product itself.⁴ Likewise, phyllanthusmin A is also built upon a diphyllin-like core, but possesses a hydroxy group at the C4 position rather than a methoxy substituent and, more importantly, does not contain the glycosidic linkage seen in other members of this group. When considering the promising activity of these compounds, it is interesting to note that diphyllin has also been shown to display cytotoxic,^{5,6} antimicrobial,⁷ and antiviral⁸ activities. Other members of the arylnaphthalene lignan class and the closely related aryltetralin lignan class of natural products have also garnered significant interest due to the range of biological activities possessed by their constituents, including cytotoxic,^{9–13} antioxidant,^{14,15} antiviral,^{16–18} anti-inflammatory,¹⁹ cardioprotective,^{20,21} insecticidal,²² and neuroprotective²³ properties. The relationship between the arylnaphthalene and aryltetralin classes of compounds is of interest due to their deceptive structural similarities as seen in Figure 1. The two classes differ, however, in the oxidation state of the B ring, imparting clear conformational differences that potentially lead to different modes of action. Despite this fact, both the aryltetralins, including etoposide and teniposide (Fig. 1B), and some arylnaphthalenes like daurinol have been shown to possess inhibitory activity against the same biological target, DNA topoisomerase II, albeit via different interactions with the enzyme as either topoisomerase poisons or catalytic inhibitors, respectively.^{24,25} In addition to mechanistic considerations, the development of etoposide and teniposide, two nearly identical clinically approved aryltetralin drugs, also points to the importance of optimization of the glycosidic moiety in

these compounds as these drugs display unique pharmacological properties²⁶ and an entirely different mechanism of action than podophyllotoxin, the aglycone from which they are derived.²⁷

Previous studies of several other structurally related aryl-naphthalene compounds have also indicated the critical importance of the glycosidic sugar moiety in mediating general antiproliferative activities within the series of aryl-naphthalene lignans.^{12,28,29} In addition to phyllanthusmins B–E,² other diphyllin glycosides, including tuberculatin⁵ and D11,²⁹ have also demonstrated more potent *in vitro* activity than diphyllin, their aglycone, in a variety of cancer cell lines. The impact of the glycosidic moiety can also be observed in the relative, although highly varied, antiproliferative activities of related natural products containing an array of substituted carbohydrate groups attached to diphyllin. The earliest examples of these are cleistanthins A³⁰ and B³¹ (as well as cleistanthin A methyl ether)¹¹ which have been thoroughly investigated for their antiproliferative properties as well as their inherent toxicities in rats.^{32–37} Acutissimalignan A, which possesses a functionalized arabinose moiety analogous to the isolated phyllanthusmins, was also recently found to possess highly potent activity against HT-29 cells following its isolation by the Kinghorn group with an IC₅₀ value of 19 nM.^{38,39} Other diphyllin glycosides that have also been found to be cytotoxic towards various cancer cell lines include patentiflorin A,⁹ procumbenoside A,⁵ and cleistanthoside A tetraacetate.^{11,40–43}

Considering the potential influence of the carbohydrate group for antiproliferative activity, this moiety was identified as a useful starting point for the exploration of the structure-activity relationships in the phyllanthusmin class of natural products. Expanding on the structure activity relationship studies reported by Shi et al and Zhao et al for this class of compounds,^{12,28} in this study we describe the synthesis of analogues containing various mono- and disaccharide units and the modification of the C-ring lactone in the aglycone portion of the molecules. The library of aryl-naphthalene lignan glycosides generated during these studies has provided important structure-activity relationship (SAR) data across a series of cell lines previously not investigated with this class of compounds, including HT-29 (colon), MDA-MB 435/231 (breast), and OVCAR3 (ovarian cancer), as well as insight into the role of DNA topoisomerase II α as a target for their antiproliferative activity.

2. Results and Discussion

Based on the relatively straightforward retrosynthetic disconnection of diphyllin from the carbohydrate moiety via the glycosidic linkage, the synthesis of analogues of the phyllanthusmin class of natural products, like other diphyllin glycosides, was predicated on the ability to efficiently produce diphyllin in sufficient quantities for derivatization. Although numerous elegant recent approaches to the synthesis of similar aryl-naphthalene core ring systems have been reported, they are either not specifically amenable to the synthesis of diphyllin or are potentially limited by scale-up cost.^{44–51} The route of Charlton and coworkers,⁵² however, has previously been employed^{12,28,53–55} for the synthesis of diphyllin and related analogues based on the ease of access to the requisite starting materials and the overall efficiency of the route. Employing only minor modifications to the reported procedure, gram scale quantities of diphyllin (**5**) have been produced (Scheme 1). The most

Author Manuscript

Author Manuscript

Author Manuscript

significant modification to the reported procedure was made based on initial difficulties observed during the isolation and purification of diphyllin following the final reduction of diester **4** using the reported sodium borohydride reduction conditions. Despite early work that indicated the potential for over-reduction of the desired lactone product in the presence of lithium aluminum hydride (LAH),⁵⁶ there was literature precedent indicating that LAH could be utilized under careful dropwise inverse addition^{44,57} or portion-wise addition⁵⁵ conditions to affect this type of transformation. In the present study, portion-wise addition of 4 equivalents of LAH cleanly and efficiently resulted in the regioselective reduction of diester **4** within five minutes as observed by thin layer chromatography. Upon workup, trituration of the crude product with methanol cleanly provided diphyllin. The overall yield of the five step sequence to prepare diphyllin ranged from 30–41% and required minimal chromatographic purification over the course of the synthesis. This method, therefore, facilitated the preparation of the aglycone in sufficient quantities for subsequent SAR studies.

Author Manuscript

Author Manuscript

Author Manuscript

With diphyllin in hand, a series of simple glycosyl bromides were prepared from the corresponding carbohydrates for glycosylation of the free phenol of the aglycone. The brominated substrates were immediately subjected to phase transfer glycosylation with diphyllin, following the same procedure implemented by Zhao and coworkers.²⁸ Utilizing this approach, the stereochemistry of the glycosidic linkage was established through neighboring group participation of the adjacent acetyl group, necessitating the presence of a C2" equatorial alcohol in all starting materials to ultimately achieve the desired stereochemical control in the glycosylation reaction. For this reason, L-arabinose, D-xylose, D-glucose, D-galactose, D-arabinose, and lactose could be effectively utilized as starting materials and were subjected to this sequence of reactions to provide phyllanthusmin (PHY) analogues **6a**, **7a**, **8a**, **9a**, **10**, and **11**, respectively (Scheme 1 and Fig. 2). Once introduced onto diphyllin, the carbohydrate substitution was then further manipulated. This was accomplished via hydrolysis of the acetylated compounds **6a–9a** to unmask the free hydroxy groups and generate compounds **6b–9b** as illustrated in Scheme 1 for compound **6**. Subsequently, the newly revealed alcohols in **6b** and **7b** were also methylated in the presence of base to provide analogues **6c** and **7c**.

Author Manuscript

Author Manuscript

During the methylation of compounds **6b** and **7b** to prepare compounds **6c** and **7c** (the natural product cleistanthin A methyl ether)¹¹, however, the formation of an additional minor byproduct was also observed in each case. The minor "impurity," although formed in only very small quantities (<2% yield), was isolated in the xylose series and was determined to be the product of ring opening of the C-ring lactone, compound **12** (Scheme 2A). Presumably, this product is generated in the presence of trace amounts of methanol (or water) through nucleophilic attack of the carbonyl and alkylation of the resulting primary alcohol.

Author Manuscript

This result, which indicates the potential instability of the lactone ring from a chemical and/or metabolic perspective, prompted further derivatization of the C-ring to probe its significance in the antiproliferative activity of these compounds. To this end, the ample supply of the precursor to diphyllin **4** facilitated generation of diester **13**, an analogue lacking the lactone ring, via phase-transfer glycosylation (Scheme 2B). Additionally,

complete removal of the lactone carbonyl oxygen of **6a**, leaving the tetrahydrofuran ring intact, was also explored. In order to efficiently access the desired ether functionality, the C7 phenol of diphyllin (**5**) was first protected as the silyl ether (Scheme 2C) and the lactone functionality was subsequently reduced utilizing a method developed by Sakai and coworkers⁵⁸ that proceeds via an $\text{InBr}_3/\text{Et}_3\text{SiH}$ radical mediated pathway. With the cyclic ether **14** in hand, synthesis of the desired analogue **17** was contingent on the deprotection of the silyl ether and the glycosylation of the resulting phenol to introduce the peracetylated arabinose moiety. In practice, this deprotection was readily accomplished using TBAF in THF to generate the free phenol **15**, which was then glycosylated to give **17**. Interestingly, however, when the deprotection reaction was run using cesium carbonate in DMF/ H_2O and left open to the air, in addition to the cleavage of the silyl ether, an unexpected oxidation also regioselectively took place at the C9 position, resulting in transposition of the lactone carbonyl and generation of the C-ring type-I lactone **16** observed in other aryl-naphthalene lignan lactone natural products including justicidin C.⁵⁹ The position of the lactone carbonyl in **16** was confirmed using a 1D Selective Gradient NOESY NMR experiment (Supplementary Information). Similar transformations resulting in the regioselective oxidation of aryl-naphthalene systems have recently also been reported by Mondal et al.⁶⁰ and Yamamoto et al.,⁵¹ with the type-I lactone being produced preferentially in both cases. Glycosylation of the free phenol of **16**, led to formation of compound **18**, containing the transposed carbonyl, but otherwise analogous to compound **6a**.

The antiproliferative activities of the synthesized analogues were first evaluated in colon carcinoma (HT-29), breast (MDA-MB-435 and MDA-MB-231; *see* Supplementary Info.), and ovarian (OVCAR3) cancer cell lines (Table 1). Structure-activity relationships were relatively consistent within both the HT-29 and MDA-MB-435 cell lines. By comparison, however, the MDA-MB-231 cell line was less susceptible to this series of compounds. The OVCAR3 cell line showed similar SAR trends to both HT-29 and MDA-MB-435, albeit with several potentially interesting outliers. In particular, analogues **7c** and **8a**, which display exceptional potency in HT-29 cells (0.018 and 0.040 μM), show a significant decrease in potency (>400 fold) against the OVCAR3 cells (8.0 and >10 μM). The observed discrepancies between cell lines, in combination with the higher potency observed in OVCAR3 versus HT-29 for compounds **7b** and **12**, suggest selectivity for specific cell lines based on the expression levels of potential cellular targets. Alternatively, this data could also point to the potential existence of multiple cellular targets within the tested cell lines. With the target(s) unknown at this time, the complete data set obtained for the test compounds against the HT-29 cell line has been utilized as the primary point of comparison and has been useful for drawing conclusions about structure-activity relationships within this series.

Against the HT-29 cells, the IC_{50} values for the acetylated diphyllin glycoside analogues **6a**–**9a**, **10** and **11** ranged in potency from 0.05 – 2.0 μM . Within this series, compounds containing a C5-hydroxymethyl group were found to have increased potency over those lacking a substituent at this position (e.g. glucosylpyranoside **8a** and galactosylpyranoside **9a** vs xylosylpyranoside **7a** and arabonsylpyranoside **6a**). It is interesting to note that compound **10**, possessing the D-arabinose group, displayed a slightly higher potency against the HT-29 cells than **6a**, the compound with the L-arabinose group found in the natural

products. Additionally, the disaccharide lactose analogue **11** resulted in the most significant loss in activity among the acetylated analogues. These observations indicate that, while a variety of different monosaccharide-containing diphyllin glycosides are well tolerated, certain disaccharide moieties may be too large to effectively elicit a biological response.

This series of synthesized analogues also allowed the relative substitution of the pendant hydroxy groups to be assessed. Compared to the acetylated compounds **6a–9a**, the corresponding free alcohol containing compounds **6b–9b** were much less active against the HT-29 cells. In fact, the glucose and galactose analogues **8b** and **9b** were found to be only weakly active or even inactive (defined in this study as having an IC_{50} of greater than 10 μ M) in both the HT-29 and OVCAR3 cell lines. These results highlight the importance of the substitution of the hydroxy groups on the sugar moieties in this series for increased antiproliferative activity. In addition, the present findings parallel previous biological results obtained from the series of isolated phyllanthusmins² in which increased potency correlated with a greater relative degree of substitution on the arabinose moiety. To support this argument, subsequent permethylation of these hydroxy groups resulted in restoration or even improvement of the antiproliferative activities. Analogue **7c**, the permethylated xylose derivative, was not only the most potent analogue synthesized in this study (0.018 μ M against HT-29), but upon comparison to **6c** (0.13 μ M) revealed a potential preference for equatorial (vs axial) stereochemistry at C4". A similar correlation has also been found with HCT116 cells in a study by Zhao *et al.*²⁸

Investigation into the SAR of the C-ring lactone of the aglycone has also determined the importance of this moiety as a part of the pharmacophore. The ring opened compounds **12** and **13** both showed a dramatic loss in potency in the HT-29 cells in comparison to their lactone counterparts (**7c** and **6a**). Similarly, removal of the carbonyl moiety (compound **17**) also reduced potency (in comparison to **6a**). Transposition of the carbonyl in compound **18** resulted in a compound with better potency than cyclic ether **17**, but still showed a 3-fold loss as compared to **6a**. These results indicate that the lactone carbonyl is an important structural motif present in the diphyllin core of the phyllanthusmins required for more potent biological activity potentially due to the electronic contribution, the induced geometry for putative binding to the target site, or a combination of the two effects.

Based on the structural similarity of the synthesized compounds to the aryltetralin etoposide and the arynaphthalene daurinol, four of the most potent analogues in the tested cell lines (**6a**, **6c**, **7c**, and **8a**) were selected for subsequent investigation of inhibitory activity against DNA topoisomerase II α and for antiproliferative activity in parental human leukemia K562 cells compared to an etoposide-resistant clonal cell line, K/VP.5, with reduced levels of DNA topoisomerase II.⁶¹ These compounds comprise a useful cross-section of the analogues, sampling a variety of glycone scaffolds and substitution, as represented by both peracetylated and permethylated derivatives of the arabinose **6**, xylose **7**, and glucose **8** analogues.

These compounds were first examined in an *in vitro* assay designed to look at the effects of purified DNA topoisomerase II α on cleavage of supercoiled pBR322 DNA. As reported previously for the natural phyllanthusmins,² the synthetic analogues did not induce DNA

topoisomerase II-mediated DNA cleavage (data not shown). However, using an assay to assess DNA topoisomerase II catalytic activity, inhibition of DNA topoisomerase II α mediated pBR322 DNA relaxation could be observed (Figure 3) for compounds **8a**, **6a**, and **7c** at 50 and 100 μ M. This activity was more pronounced than that of diphyllin itself, although the compounds were not as potent as etoposide (100 μ M). Compound **6c** does not appear to show any activity in the DNA relaxation assay and, therefore, suggests some structural specificity required for inhibition of DNA topoisomerase II α catalytic activity. Based on their observed inhibitory activity against isolated enzyme, the antiproliferative activity of these compounds was evaluated in etoposide sensitive K562 cells and in acquired etoposide resistant K/VP.5 cells, which contain \sim 1/5 the level of DNA topoisomerase II α compared to parental K562 cells and which have been shown to be 30-fold resistant to etoposide in direct growth inhibition assays.^{61,62} The antiproliferative activities observed for the four compounds in both cell lines were nearly identical (Table 2), strongly suggesting that direct DNA topoisomerase II α inhibition is not likely the primary mechanism of action through which these compounds mediate their effects on cancer cells.

3. Conclusions

Members of the phyllanthusmin class of natural products represent promising lead compounds based on their potent cytotoxic properties. This study has demonstrated that variation of the carbohydrate portion of these compounds is well tolerated with regard to observed antiproliferative activities and establishes a foundation for future studies within this class of compounds. The mechanism(s) of action of this class remains to be determined, although evidence presented here and elsewhere suggests that DNA topoisomerase II α activity is not a significant contributor.² The selectivity observed for some of the compounds across the cell lines tested suggests that specific analogues may affect multiple targets within the various cancer subtypes or are dramatically affected by their relative expression levels within cells. The potential flexibility afforded by the structural variation of the carbohydrate moiety may ultimately prove to be useful for the development of novel agents with optimal physicochemical properties and could potentially be exploited to promote target selectivity in future generations of analogues.

4. Experimentals

4.1. Chemistry

All reactions were performed at room temperature, under an argon atmosphere, with reagent grade solvents unless otherwise stated. Commercially available chemicals were used without further purification. When applicable, dry solvents (THF, DCM, and DMF) were obtained from an Innovative Technology PureSolv system and oven-dried syringes were used to transfer air and moisture sensitive liquids. Reactions were monitored by thin layer chromatography (TLC) using aluminum backed pre-coated silica gel plates (w/UV254, 200 μ m) from Sorbtech, using UV light as the visualizing agent and ceric ammonium molybdate (CAM) and heat as a developing agent. Flash column chromatography was carried out using Sorbtech 40–63 μ m silica gel with eluent ratios expressed in v/v. All ¹H- and ¹³C-NMR spectra were recorded at 300 K on a Bruker AV300, AVIII400, or DRX400 MHz NMR with

tetramethylsilane as an internal standard. Chemical shifts (δ) are reported in parts per million (ppm) with multiplicities when applicable (s = singlet, d = doublet, t = triplet, dd = doublet of doublets, m = multiplet, etc.), and are calibrated using the residual undeuterated solvent peak (CDCl₃: δ 7.26 ppm ¹H NMR, 77.16 ppm ¹³C NMR; acetone-d₆: δ 2.05 ppm ¹H NMR, 29.84 ppm ¹³C NMR; DMSO-d₆: δ 2.50 ppm ¹H NMR, 39.52 ppm ¹³C NMR; CD₃OD: δ 3.31 ppm ¹H NMR, 49.00 ppm ¹³C NMR). As previously described by Charlton et al.,⁵¹ the hindered rotation of aryl naphthalene lignans about the C1'-C7' bond results in observation of "additional" peaks in several ¹H and ¹³C NMR spectra, an effect that appears to be highly solvent dependent. High resolution electrospray ionization mass spectra (HRMS-ESI) were recorded on a Thermo LTQ Orbitrap mass spectrometer. Melting points were recorded using a Thomas Hoover Melting Point Capillary Apparatus. Infrared (IR) absorption spectra were recorded on Thermo-Nicolet 6700 FTIR. Prior to biological testing, purity was determined using an ACE Excel 3 C18-PFP (150 × 4.6 mm) column on a Shimadzu HPLC system (flow rate: 1 mL/min).

4.1.1. Preparation of diphyllin (5)—Diphyllin was synthesized according to the method of Charlton and coworkers,⁵² albeit with a slight modification to the last step. For the final reduction step, the diester **4** (5.86 g, 12.5 mmol) was dissolved in dry THF (250 mL) and lithium aluminum hydride (1.90 g, 50 mmol) was added portion-wise at 0 °C. The reaction mixture was allowed to warm to room temperature over a 5 minute period prior to being cooled back to 0 °C and quenched via the dropwise addition of deionized water. Once the evolution of gas was no longer observed upon further addition of water, the pH of the mixture was brought to ~2 with the slow addition of 2M HCl. The resulting aqueous mixture was then extracted three times with EtOAc. The combined organic layers were washed with brine, dried with sodium sulfate, and concentrated under reduced pressure. Trituration of the resulting crude solid with methanol provided diphyllin (3.17 g, 67%) as a pale yellow solid. The ¹H and ¹³C spectral characteristics were identical to those previously published.⁵² ¹H NMR (400 MHz, Acetone-d₆) δ 9.24 (br s, 1H), 7.69 (s, 1H), 7.09 (s, 1H), 6.96 (d, J = 7.9 Hz, 1H), 6.85 (d, J = 1.6 Hz, 1H), 6.80 (dd, J = 7.9, 1.7 Hz, 1H), 6.09 (d, J = 1.0 Hz, 1H), 6.08 (d, J = 1.0 Hz, 1H), 5.37 (s, 2H), 4.00 (s, 3H), 3.73 (s, 3H); ¹³C NMR (101 MHz, Acetone-d₆) δ 170.27, 152.21, 151.35, 148.31, 148.05, 145.69, 131.70, 131.19, 130.24, 124.80, 124.53, 122.83, 119.99, 112.01, 108.59, 106.87, 102.09, 101.34, 66.99, 56.09, 55.74; HRMS-ESI calcd for C₂₁H₁₆O₇ (M+Na)⁺ 403.07882, found 403.07855.

4.1.2. Synthesis of per-acetylated diphyllin glycosides

4.1.2.1. General procedure for bromination/glycosylation

7-O-(2'',3'',4'',6''-Tetra-O-acetyl- β -D-glucopyranosyl) diphyllin (8a): To 1,2,3,4,6-penta-O-acetyl-D-glucopyranose (1.678 g, 4.30 mmol) dissolved in DCM (10.75 mL) was added hydrogen bromide (33% in acetic acid, 2.97 mL) dropwise at 0 °C. The reaction mixture was then allowed to warm to room temperature and stir for an additional 4 h. The reaction was quenched with water and the aqueous layer was extracted with DCM. The organic layers were combined and washed with water, saturated aqueous NaHCO₃, brine, and then dried with sodium sulfate and concentrated under reduced pressure to afford a clear viscous oil that was immediately added to a biphasic mixture of diphyllin (1.090 g, 2.87 mmol) and TBAB (0.933 g, 2.89 mmol) in CHCl₃ (100 mL) and aqueous NaOH (0.1 M, 100 mL) at

40 °C. The mixture was maintained at 40 °C overnight. After cooling to room temperature, the layers were separated and the aqueous layer was extracted three times with CHCl₃. The combined organic layers were washed with brine, dried with sodium sulfate, and concentrated under reduced pressure. Flash chromatography (silica gel, 0.3% → 1% MeOH in CHCl₃) afforded compound **8a** (1.928 g, 95%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 7.52 (s, 1H), 7.07 (s, 1H), 6.96 (d, *J* = 7.8 Hz, 1H), 6.82 (br s, 1H), 6.79 (br d, *J* = 7.9 Hz, 1H), 6.09 (br s, 1H), 6.05 (br s, 1H), 5.56 – 5.48 (m, 2H), 5.40 (br d, *J* = 14.8, 1H), 5.33 (t, *J* = 9.5 Hz, 1H), 5.23 – 5.14 (m, 2H), 4.27 (dd, *J* = 12.4, 6.0 Hz, 1H), 4.14 (br d, *J* = 12.4 Hz, 1H), 4.06 (s, 3H), 3.80 (s, 3H), 3.79 – 3.75 (m, 1H), 2.11 (s, 3H), 2.06₂ (s, 3H), 2.05₇ (s, 3H), 2.04 (br s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.50, 170.27, 169.52, 169.51, 169.45, 152.14, 150.58, 147.73, 147.71, 147.69, 144.13, 144.12, 136.53, 130.87, 128.22, 127.06, 127.05, 126.30, 126.28, 123.68, 123.63, 119.32, 110.75, 110.73, 108.37, 108.34, 106.31, 101.41, 101.00, 100.99, 100.60, 100.58, 72.69, 71.75, 68.26, 66.93, 62.03, 56.32, 55.98, 20.99, 20.70, 20.68; HRMS-ESI calcd for C₃₅H₃₄O₁₆ (M+Na)⁺ 733.17391, found 733.17317.

4.1.2.2. 7-O-(2'',3'',4''-Tri-O-acetyl-α-L-arabinopyranosyl) diphyllin (6a): Starting from

1,2,3,4-tetra-*O*-acetyl-L-arabinopyranose and following the general procedure for bromination/glycosylation, flash chromatography (silica gel, 45% → 52% EtOAc in hexanes) afforded **6a** (702 mg, 84%) as a white solid: $[\alpha]_D^{20} - 7.59^\circ$ (*c* 0.24, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.54 (s, 1H), 7.08 (s, 1H), 6.96 (d, *J* = 7.8 Hz, 1H), 6.84 – 6.76 (m, 2H), 6.09 (br s, 1H), 6.05 (br s, 1H), 5.70 (dd, *J* = 9.5, 7.0 Hz, 1H), 5.48 (d, *J* = 14.8 Hz, 1H), 5.41 (br d, *J* = 14.8 Hz, 1H), 5.39 – 5.35 (m, 1H), 5.17 (dd, *J* = 9.5, 3.5 Hz, 1H), 5.09 (d, *J* = 7.0 Hz, 1H), 4.19 (dd, *J* = 13.0, 3.1 Hz, 1H), 4.09 (s, 3H), 3.80 (s, 3H), 3.72 (br d, *J* = 12.7 Hz, 1H), 2.22 (s, 3H), 2.11 (s, 3H), 2.08 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.31, 170.17, 169.60, 169.55, 152.08, 150.50, 147.65, 144.28, 136.26, 130.85, 128.33, 127.31, 126.28, 123.66, 123.64, 119.41, 110.76, 108.30, 106.35, 101.48, 101.37, 100.61, 100.60, 70.26, 69.53, 67.41, 66.98, 64.09, 56.35, 55.95, 21.07, 21.04, 20.78; HRMS-ESI calcd for C₃₂H₃₀O₁₄ (M+Na)⁺ 661.15278, found 661.15218.

4.1.2.3. 7-O-(2'',3'',4''-Tri-O-acetyl-β-D-xylopyranosyl) diphyllin (7a): Starting from

1,2,3,4-tetra-*O*-acetyl-D-xylopyranose and following the general procedure for bromination/glycosylation, flash chromatography (silica gel, 45% → 55% EtOAc in hexanes) afforded **7a** (511 mg, 87%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 7.49 (s, 1H), 7.04 (s, 1H), 6.91 (d, *J* = 7.7 Hz, 1H), 6.80 – 6.70 (m, 2H), 6.06 (s, 1H), 6.01 (s, 1H), 5.44 (dd, *J* = 9.0, 7.3 Hz, 1H), 5.43 (d, *J* = 15.2 Hz), 5.38 (br d, *J* = 15.2 Hz, 1H), 5.30 (t, *J* = 8.9 Hz, 1H), 5.13 (d, *J* = 7.0 Hz, 1H), 5.11 (dd, *J* = 8.6, 5.1 Hz, 1H), 4.25 (dd, *J* = 11.8, 5.2 Hz, 1H), 4.05 (s, 3H), 3.78 (s, 3H), 3.41 (dd, *J* = 11.7, 9.3 Hz, 1H), 2.11 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.19, 169.94, 169.51, 169.50, 152.13, 150.53, 147.70, 147.68, 147.67, 144.12, 144.11, 136.48, 130.89, 128.28, 127.89, 127.88, 126.47, 126.45, 123.69, 123.66, 119.42, 119.42, 110.77, 108.35, 108.33, 106.39, 101.59, 101.39, 100.54, 100.52, 71.80, 71.49, 68.80, 66.89, 62.97, 56.37, 55.97, 20.98, 20.82, 20.82; HRMS-ESI calcd for C₃₂H₃₀O₁₄ (M+Na)⁺ 661.15278, found 661.15210.

4.1.2.4. 7-O-(2'',3'',4'',6'')-Tetra-O-acetyl-β-D-galactopyranosyl) diphyllin (9a): Starting from 1,2,3,4,6-penta-*O*-acetyl-*D*-galactopyranose and following the general procedure for bromination/glycosylation, flash chromatography (silica gel, 50% EtOAc in hexanes) provided compound **9a** (444 mg, 68%) as an off-white solid: ¹H NMR (400 MHz, CDCl₃) δ 7.54 (s, 1H), 7.05 (s, 1H), 6.94 (d, *J* = 7.9 Hz, 1H), 6.80 (s, 1H), 6.77 (br d, *J* = 4.9 Hz, 1H), 6.07 (br s, 1H), 6.03 (d, *J* = 5.2 Hz, 1H), 5.71 (dd, *J* = 10.2, 8.1 Hz, 1H), 5.55 (d, *J* = 14.7 Hz, 1H), 5.49 (d, *J* = 2.7 Hz, 1H), 5.39 (br d, *J* = 14.7 Hz, 1H), 5.20 – 5.11 (m, 2H), 4.26 – 4.14 (m, 2H), 4.07 (s, 3H), 4.07 – 4.03 (m, 1H), 3.79 (s, 3H), 2.23 (s, 3H), 2.07 (s, 3H), 2.03 (br s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 170.46, 170.22, 170.08, 169.68, 169.47, 169.46, 152.07, 150.55, 147.66, 144.41, 136.13, 130.78, 128.30, 125.93, 125.90, 125.65, 125.62, 123.65, 123.62, 119.35, 119.34, 110.74, 108.32, 108.30, 106.23, 101.37, 101.14, 101.13, 100.69, 100.66, 71.99, 70.78, 69.19, 67.10, 67.03, 61.95, 56.38, 55.94, 21.10, 20.77, 20.69, 20.64; HRMS-ESI calcd for C₃₅H₃₄O₁₆ (M+Na)⁺ 733.17391, found 733.17368.

4.1.2.5. 7-O-(2'',3'',4'')-Tri-O-acetyl-α-D-arabinopyranosyl) diphyllin (10): Starting from 1,2,3,4-tetra-*O*-acetyl-*D*-arabinopyranose and following the general procedure for bromination/glycosylation, flash chromatography afforded compound **10**: [α]_D²⁰ + 11.1° (c 0.43, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.54 (s, 1H), 7.07 (s, 1H), 6.96 (d, *J* = 7.8 Hz, 1H), 6.85 – 6.76 (m, 2H), 6.10 (d, *J* = 1.4 Hz, 1H), 6.05 (br s, 1H), 5.70 (dd, *J* = 9.6, 7.0 Hz, 1H), 5.49 (d, *J* = 14.8 Hz, 1H), 5.42 (br d, *J* = 14.7 Hz, 1H), 5.39 – 5.36 (m, 1H), 5.17 (dd, *J* = 9.6, 3.5 Hz, 1H), 5.09 (d, *J* = 7.0 Hz, 1H), 4.19 (dd, *J* = 13.1, 3.1 Hz, 1H), 4.09 (s, 3H), 3.81 (s, 3H), 3.72 (dd, *J* = 13.0, 1.3 Hz, 1H), 2.22 (s, 3H), 2.11 (s, 3H), 2.08 (s, 3H); HRMS-ESI calcd for C₃₂H₃₀O₁₄ (M+Na)⁺ 661.15278, found 661.15188.

4.1.2.6. 7-O-(Hepta-O-acetyl-β-D-galactopyranosyl-(1→4)-D-glucopyranosyl) diphyllin (11): Starting from lactose octaacetate and following the general procedure for bromination/glycosylation, flash chromatography afforded compound **11**: ¹H NMR (400 MHz, CDCl₃) δ 7.47 (s, 1H), 7.07 (s, 1H), 6.96 (dd, *J* = 7.8, 1.6 Hz, 1H), 6.83 – 6.77 (m, 2H), 6.09 (br s, 1H), 6.05 (br s, 1H), 5.50 (br d, *J* = 14.8, 1H), 5.46 – 5.40 (m, 2H), 5.39 – 5.36 (m, 1H), 5.34 – 5.29 (m, 1H), 5.16 – 5.09 (m, 2H), 5.01 – 4.96 (m, 1H), 4.52 (d, *J* = 7.9 Hz, 1H), 4.49 (br d, *J* = 10.3 Hz, 1H), 4.19 – 4.06 (m, 4H), 4.05 (s, 3H), 3.93 – 3.86 (m, 2H), 3.80 (s, 3H), 3.74 – 3.68 (m, 1H), 2.16 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 2.06 (d, *J* = 2.0 Hz, 3H), 2.04 (s, 3H), 1.97 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.50, 170.29, 170.22, 170.16, 169.80, 169.78, 169.48, 169.23, 152.15, 150.57, 147.73, 147.71, 147.70, 144.08, 136.45, 130.88, 128.26, 127.09, 126.11, 126.10, 123.70, 123.66, 119.38, 110.76, 108.38, 106.38, 101.41, 101.30, 100.83, 100.41, 100.38, 76.30, 73.63, 72.79, 72.04, 71.01, 70.99, 69.20, 66.99, 66.74, 62.12, 60.96, 56.34, 55.99, 21.04, 20.89, 20.78, 20.78, 20.77, 20.72, 20.63; HRMS-ESI calcd for C₄₇H₅₀O₂₄ (M+Na)⁺ 1021.25842, found 1021.25795.

4.1.3. Synthesis of per-hydroxy diphyllin glycosides

4.1.3.1. General procedure for global deacetylation

7-O-α-L-arabinopyranosyl diphyllin (6b): To a solution of **6a** (324.4 mg, 0.511 mmol) in methanol (32 mL) was added K₂CO₃ (284 mg, 2.05 mmol) and the resulting mixture was stirred at room temperature for 30 minutes. The reaction was then quenched via the addition

of aqueous HCl (2 M), filtered through filter paper, and concentrated under reduced pressure. Flash chromatography (silica gel, 2% → 10% MeOH in CHCl₃) afforded compound **6b** (259 mg, 99%) as an off white solid: ¹H NMR (400 MHz, (CD₃)₂SO) δ 8.17 (s, 1H), 7.04 (d, *J* = 7.9 Hz, 1H), 6.98 (d, *J* = 2.3 Hz, 1H), 6.93 (br s, 1H), 6.80 (br d, *J* = 7.9, 1H), 6.13 (s, 2H), 5.81 – 5.76 (m, 1H), 5.53 (br d, *J* = 14.8 Hz, 1H), 5.45 (d, *J* = 15.0 Hz, 1H), 5.06 (d, *J* = 5.0 Hz, 1H), 4.79 (t, *J* = 7.1 Hz, 1H), 4.76 (d, *J* = 3.7 Hz, 1H), 3.94 (s, 3H), 3.84 (br dd, *J* = 12.2, 6.5 Hz, 1H), 3.77 (br d, *J* = 11.5 Hz, 1H), 3.70 (br s, 1H), 3.67 (s, 3H), 3.52 (br s, 1H), 3.44 (d, *J* = 11.5 Hz, 1H); ¹³C NMR (75 MHz, (CD₃)₂SO) δ 169.00, 151.39, 149.95, 146.90, 146.84, 144.57, 134.49, 134.44, 129.68, 128.87, 128.70, 128.24, 126.60, 123.57, 118.65, 110.84, 110.77, 107.91, 105.41, 104.82, 104.70, 101.86, 101.08, 72.24, 70.82, 67.25, 67.21, 67.03, 65.71, 65.65, 55.81, 55.19; HRMS-ESI calcd for C₂₆H₂₄O₁₁ (M + Na)⁺ 535.12108, found 535.12058.

4.1.3.2. 7-O-β-D-Xylopyranosyl diphyllin (7b): Starting from **7a** and following the general procedure for global deacetylation, flash chromatography (2% → 10% MeOH in CHCl₃) afforded compound **7b** (67 mg, 88%) as a white solid: ¹H NMR (400 MHz, (CD₃)₂SO) δ 8.12 (br s, 1H), 7.04 (d, *J* = 7.9 Hz, 1H), 6.99 (s, 0.5H), 6.98 (s, 0.5H), 6.93 (d, *J* = 1.6 Hz, 0.5H), 6.91 (d, *J* = 1.6 Hz, 0.5H), 6.80 (dd, *J* = 7.9, 1.8 Hz, 0.5H), 6.79 (dd, *J* = 7.9, 1.8 Hz, 0.5H), 6.12 (br s, 2H), 5.93 (dd, *J* = 5.4, 2.9 Hz, 1H), 5.51 (br d, *J* = 15.2 Hz, 1H), 5.44 (d, *J* = 15.1 Hz, 1H), 5.23 (d, *J* = 4.9 Hz, 1H), 5.07 (d, *J* = 4.8 Hz, 1H), 4.76 (dd, *J* = 7.6, 4.8 Hz, 1H), 3.94 (s, 3H), 3.81 (dd, *J* = 11.3, 5.2 Hz, 1H), 3.67 (s, 3H), 3.50 – 3.40 (m, 2H), 3.29 – 3.22 (m, 1H), 3.18 – 3.08 (m, 1H); ¹³C NMR (101 MHz, (CD₃)₂SO) δ 169.04, 151.47, 149.96, 146.94, 146.92, 146.89, 144.71, 144.68, 134.92, 134.89, 129.78, 129.74, 129.73, 129.65, 128.18, 126.70, 126.69, 123.59, 123.55, 118.69, 110.86, 110.75, 107.95, 107.92, 105.73, 105.68, 105.47, 101.64, 101.11, 79.16, 76.29, 73.59, 69.30, 67.00, 65.90, 55.82, 55.21; HRMS-ESI calcd for C₂₆H₂₄O₁₁ (M+K)⁺ 551.09502, found 551.09371.

4.1.3.3. 7-O-β-D-Glucopyranosyl diphyllin (8b): Starting from **8a** and following the general procedure for global deacetylation, flash chromatography (2% → 10% MeOH in CHCl₃) afforded compound **8b** (49.9 mg, 98%) as a white solid: ¹H NMR (400 MHz, (CD₃)₂SO) δ 8.19 (s, 0.5H), 8.18 (s, 0.5H), 7.04 (d, *J* = 7.9 Hz, 1H), 6.98₂ (s, 0.5H), 6.97₆ (s, 0.5H), 6.96 (d, *J* = 1.4 Hz, 0.5H), 6.92 (d, *J* = 1.6 Hz, 0.5H), 6.81 (dd, *J* = 8.1, 1.7 Hz, 0.5H), 6.79 (dd, *J* = 8.0, 1.7 Hz, 0.5H), 6.13 (br s, 2H), 5.99 (dd, *J* = 5.3, 2.9 Hz, 1H), 5.77 (d, *J* = 15.4 Hz, 1H), 5.48 (br d, *J* = 15.5, 1H), 5.25 (d, *J* = 5.0 Hz, 1H), 5.09 (d, *J* = 5.2 Hz, 1H), 4.77 – 4.72 (m, 1H), 4.70 (dd, *J* = 10.8, 5.4 Hz, 1H), 3.95 (s, 3H), 3.77 (br dd, *J* = 11.2, 4.7 Hz, 1H), 3.67 (s, 3H), 3.50 – 3.42 (m, 2H), 3.32 – 3.20 (m, 2H), 3.18 – 3.11 (m, 1H); ¹³C NMR (101 MHz, (CD₃)₂SO) δ 169.22, 151.46, 149.95, 146.96, 146.95, 146.90, 144.86, 144.83, 134.94, 134.88, 130.02, 129.88, 129.68, 128.29, 126.78, 126.74, 123.63, 123.57, 118.85, 110.94, 110.79, 107.97, 105.39, 105.12, 105.07, 101.75, 101.15, 77.28, 76.35, 73.79, 70.06, 67.42, 61.30, 55.86, 55.22; HRMS-ESI calcd for C₂₇H₂₆O₁₂ (M+Na)⁺ 565.13165, found 565.13081.

4.1.3.4. 7-O-β-D-Galactopyranosyl diphyllin (9b): Starting from **9a** and following the general procedure for global deacetylation, flash chromatography afforded **9b** as a white solid: ¹H NMR (400 MHz, DMSO) δ 8.20₃ (s, 0.5H), 8.19₆ (s, 0.5H), 7.04 (d, *J* = 7.9 Hz,

1H), 6.98₃ (s, 0.5H), 6.97₉ (s, 0.5H), 6.95 (d, *J* = 1.4 Hz, 0.5H), 6.91 (d, *J* = 1.4 Hz, 0.5H), 6.83 – 6.77 (m, 1H), 6.13 (br s, 2H), 5.77 (dd, *J* = 5.3, 2.8 Hz, 1H), 5.70 (d, *J* = 15.3 Hz, 1H), 5.49 (br d, *J* = 15.2 Hz, 1H), 4.97 (d, *J* = 5.7 Hz, 1H), 4.71 (dd, *J* = 7.3, 6.4 Hz, 1H), 4.68 (dd, *J* = 9.6, 4.7 Hz, 1H), 4.61 (d, *J* = 4.3 Hz, 1H), 3.95 (s, 3H), 3.82 – 3.75 (m, 1H), 3.69 – 3.66 (m, 1H), 3.67 (s, 3H), 3.64 – 3.56 (m, 2H), 3.50 – 3.40 (m, 2H); ¹³C NMR (101 MHz, DMSO) δ 169.16, 151.40, 149.92, 146.92, 146.85, 145.00, 144.97, 134.77, 129.76, 129.67, 129.61, 128.29, 126.76, 123.60, 123.52, 118.80, 110.89, 110.73, 107.93, 105.69, 105.64, 105.40, 101.85, 101.09, 75.91, 73.09, 70.81, 68.43, 67.35, 60.97, 55.81, 55.19; HRMS-ESI calcd for C₂₇H₂₆O₁₂ (M+H)⁺ 543.14970, found 543.14940.

4.1.4. Synthesis of per-methylated diphyllin glycosides

4.1.4.1. General procedure for global methylation

7-O-(2'',3'',4''-Tri-O-methoxy- α -L-arabinopyranosyl) diphyllin (6c): Sodium hydride (43 mg, 1.072 mmol) was added to a solution of **6b** (137.5 mg, 0.268 mmol) in DMF (3.58 mL) at 0 °C and stirred for 30 minutes prior to the dropwise addition of methyl iodide (133 μ L, 2.144 mmol). The reaction was then stirred at 80 °C overnight. Upon cooling to room temperature, the reaction was quenched with water and extracted with a mixture of EtOAc/hexanes (1:1). The combined organic layers were washed with water, brine, and then dried with sodium sulfate and concentrated under reduced pressure. Flash column chromatography (65% → 75% EtOAc in hexanes) afforded compound **6c** (107 mg, 72%) as an off white solid: ¹H NMR (300 MHz, CDCl₃) δ 7.92 (s, 1H), 7.08 (s, 1H), 6.95 (d, *J* = 7.6, 1H), 6.85 – 6.77 (m, 2H), 6.09 (d, *J* = 1.5 Hz, 1H), 6.04 (d, *J* = 1.4 Hz, 1H), 5.55 (br d, *J* = 15.2 Hz, 1H), 5.46 (br d, *J* = 15.2 Hz, 1H), 4.77 (d, *J* = 7.3 Hz, 1H), 4.14 (br dd, *J* = 13.0, 2.6 Hz, 1H), 4.07 (s, 3H), 3.81 (s, 3H), 3.80 (s, 3H), 3.78 – 3.73 (m, 1H), 3.66 – 3.63 (m, 1H), 3.57 (s, 3H), 3.53 (s, 3H), 3.34 (dd, *J* = 9.2, 3.4 Hz, 1H), 3.22 (br d, *J* = 12.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 169.99, 152.00, 150.30, 147.63, 144.63, 136.35, 130.94, 130.87, 130.83, 128.58, 127.24, 123.80, 123.68, 119.43, 110.91, 110.81, 108.34, 108.29, 106.36, 105.06, 101.35, 101.07, 82.58, 80.61, 74.49, 67.72, 62.40, 61.50, 58.00, 57.56, 56.30, 55.96; HRMS-ESI calcd for C₂₉H₃₀O₁₁ (M+Na)⁺ 577.16803, found 577.16735.

4.1.4.2. 7-O-(2'',3'',4''-Tri-O-methoxy- β -D-xylopyranosyl) diphyllin (7c) and methyl 1-(benzof[d][1,3]dioxol-5-yl)-6,7-dimethoxy-3-(methoxymethyl)-4-(((2S,3R,4S,5R)-3,4,5-trimethoxytetrahydro-2H-pyran-2-yl)oxy)-2-naphthoate (12): Starting from **7b** and following the general procedure for global methylation, flash chromatography (5% EtOH, 1% EtOAc in Hexanes) afforded compound **7c** (R_f = 0.23 in a 20:7.5:72.5 mixture of EtOAc/EtOH/Hex, 60 mg, 56%) as an off-white solid as well as byproduct **12** (R_f = 0.26 in a 20:7.5:72.5 mixture of EtOAc/EtOH/Hex, 2 mg, 1.7%) as a white solid. **7c:** ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.09 (s, 1H), 6.96 (br d, *J* = 7.2, 1H), 6.85 – 6.78 (m, 2H), 6.09 (br s, 1H), 6.05 (br s, 1H), 5.51 (d, *J* = 15.1, 1H), 5.42 (d, *J* = 15.0, 1H), 4.77 (d, *J* = 7.6 Hz, 1H), 4.08 (s, 3H), 4.05 – 3.99 (m, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.68 (s, 3H), 3.49 (s, 3H), 3.43 – 3.35 (m, 2H), 3.22 (t, *J* = 8.7 Hz, 1H), 3.05 (dd, *J* = 11.6, 10.0 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 169.91, 152.10, 150.33, 147.66, 144.47, 136.57, 131.16, 131.13, 130.99, 128.51, 127.20, 123.77, 123.72, 119.42, 110.87, 110.83, 108.33, 106.46, 105.30, 101.37, 100.82, 85.67, 83.64, 79.53, 77.58, 77.16, 76.74, 67.46, 63.64, 61.42, 60.89, 58.92, 56.27, 55.98; HRMS-ESI calcd for C₂₉H₃₀O₁₁ (M+Na)⁺ 577.16803, found 577.16722. **12:**

$[\alpha]_D^{20} - 16.7^\circ$ (*c* 0.09, CHCl₃); IR ν_{\max} (KBr, cm⁻¹): 2930, 2831, 1724, 1623, 1508; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 6.91 – 6.75 (m, 4H), 6.05 (br s, 1H), 6.02 (br s, 1H), 4.95 (dd, *J* = 12.9, 11.6 Hz, 1H), 4.77 – 4.68 (m, 2H), 4.04 (s, 3H), 3.94 (dd, *J* = 11.8, 5.4 Hz, 1H), 3.83 (s, 3H), 3.77₂ (s, 1.5H), 3.76₆ (s, 1.5H), 3.68 (s, 3H), 3.56 (s, 1.5H), 3.55 (s, 1.5H), 3.48 (s, 3H), 3.44 – 3.33 (m, 3H), 3.31₉ (s, 1.5H), 3.31₇ (s, 1.5H), 3.22 – 3.16 (m, 1H), 2.97 – 2.90 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 169.97, 169.94, 150.46, 150.45, 150.09, 148.65, 148.60, 147.47, 147.39, 147.10, 147.06, 133.71, 131.91, 130.57, 129.30, 129.25, 124.14, 124.05, 124.01, 123.58, 111.08, 110.74, 108.20, 108.15, 106.00, 105.98, 105.53, 102.26, 102.24, 101.24, 86.04, 84.32, 84.31, 79.74, 67.01, 63.78, 61.44, 60.95, 58.92, 58.36, 58.35, 56.17, 55.90, 55.88, 51.85, 51.84, 29.85; HRMS-ESI calcd for C₃₁H₃₆O₁₂ (M+Na)⁺ 623.20990, found 623.21148; mp 76–78 °C.

4.1.5. Preparation of lactone (C-ring) analogues

4.1.5.1. Diethyl 1-(benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-4-(((2*S*,3*R*,4*S*,5*S*)-3,4,5-triacetoxytetrahydro-2*H*-pyran-2-yl)oxy)naphthalene-2,3-dicarboxylate (13**):** Starting from 1,2,3,4-tetra-*O*-acetyl-L-arabinopyranose and following the general procedure for bromination/glycosylation using **4** (the diester precursor to diphyllin) as the glycosidic acceptor, flash chromatography afforded compound **13** (105 mg, 45%) as a white solid:

$[\alpha]_D^{20} 17.2^\circ$ (*c* 0.20, CHCl₃); IR ν_{\max} (KBr, cm⁻¹): 3070, 2981, 2938, 2904, 2833, 2777, 1747, 1684, 1621; ¹H NMR (300 MHz, CDCl₃) δ 7.64 (s, 1H), 7.62 (s, 1H), 6.93–6.68 (m, 5H), 6.82 – 6.76 (m, 2H), 6.73 – 6.69 (m, 1H), 6.07 (d, *J* = 1.4 Hz, 1H), 6.06 (d, *J* = 1.4 Hz, 1H), 6.02 (d, *J* = 1.5 Hz, 1H), 6.01 (d, *J* = 1.5 Hz, 1H), 5.68 (dd, *J* = 7.0, 1.4 Hz, 1H), 5.65 (dd, *J* = 6.8, 1.4 Hz, 1H), 5.32 – 5.27 (m, 2H), 5.16 (d, *J* = 6.5 Hz, 1H), 5.14 (d, *J* = 6.5 Hz, 1H), 5.13 (dd, *J* = 3.3, 1.5 Hz, 1H), 5.10 (dd, *J* = 3.5, 1.3 Hz, 1H), 4.42 – 4.30 (m, 4H), 4.05 (br s, 6H), 4.05 – 3.98 (m, 4H), 3.78 (s, 3H), 3.77 (s, 3H), 3.55₂ (d, *J* = 13.0 Hz, 1H), 3.54₆ (d, *J* = 12.9 Hz, 1H), 2.16 (br s, 6H), 2.14 (s, 3H), 2.13 (s, 3H), 2.08 (br s, 6H), 1.40 (t, *J* = 7.2 Hz, 3H), 1.39₅ (t, *J* = 7.2 Hz, 3H), 1.03 (t, *J* = 7.2 Hz, 3H), 1.02₇ (t, *J* = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 170.34, 170.23, 169.71, 169.65, 168.13, 168.10, 166.44, 166.37, 151.22, 150.73, 150.70, 148.47, 148.43, 147.61, 147.48, 147.34, 147.28, 134.29, 134.27, 131.51, 131.42, 130.54, 130.52, 128.65, 128.51, 125.08, 124.96, 123.85, 123.33, 120.71, 120.44, 110.91, 110.52, 108.32, 108.23, 105.79, 102.80, 102.73, 102.67, 101.30, 70.31, 69.56, 69.52, 67.63, 63.69, 63.65, 61.76, 61.33, 56.11, 55.93, 55.90, 21.04, 21.00, 20.85, 14.17, 13.88; HRMS-ESI calcd for C₃₆H₃₈O₁₆ (M+Na)⁺ 749.20521, found 749.20282; mp 117–119 °C.

4.1.5.2. ((9-(Benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-1,3-dihydronaphtho[2,3-*cl*furane-4-yl)oxy)(tertbutyl) dimethylsilane (14**):** A solution of diphyllin **5** (0.987 g, 2.595 mmol), TBSCl (1.173 g, 7.785 mmol), and imidazole (0.618 g, 9.083 mmol) in DMF (26 mL) was reacted at room temperature overnight. The reaction was quenched with water and extracted with EtOAc. The combined organic layers were washed with cold water, brine, and then dried over magnesium sulfate before being concentrated under reduced pressure. Flash column chromatography (2:1:17 EtOAc/DCM/Hex → 3:1:16 EtOAc/DCM/Hex) afforded TBS-protected diphyllin (828 mg, 65%) as a white crystalline solid: IR ν_{\max} (KBr, cm⁻¹): 3074, 3010, 2955, 2932, 2887, 2859, 2831, 2776, 2255, 1766, 1613, 1599, 1507; ¹H NMR

(400 MHz, CDCl₃) δ 7.46 (s, 1H), 7.08 (s, 1H), 6.96 (d, *J* = 7.8 Hz, 1H), 6.85 (d, *J* = 1.4 Hz, 1H), 6.81 (dd, *J* = 7.9, 1.7 Hz, 1H), 6.09 (d, *J* = 1.4 Hz, 1H), 6.05 (d, *J* = 1.4 Hz, 1H), 5.33 (s, 2H), 4.04 (s, 3H), 3.81 (s, 3H), 1.15 (s, 9H), 0.29 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 170.10, 162.47, 151.24, 150.17, 147.62, 147.52, 143.68, 133.56, 130.96, 128.74, 127.04, 126.54, 123.88, 119.49, 111.02, 108.27, 106.47, 101.31, 67.04, 56.18, 55.94, 25.97, 18.73, -3.05; HRMS-ESI calcd for C₂₇H₃₀O₇Si (M+Na)⁺ 517.16530, found 517.16563; mp 190–191.5 °C. Following the procedure reported by Sakai and coworkers for the reduction of lactones,⁵⁴ a reaction vial, charged with TBS-protected diphyllin (0.128 g, 0.259 mmol), was flushed with argon several times using a schlenck line. The starting material was then dissolved with freshly distilled CHCl₃ (0.26 mL) prior to the successive addition of InBr₃ (0.005 g, 0.013 mmol) and Et₃SiH (0.165 mL, 1.036 mmol). The vial was immediately capped, shaken, and then stirred at 60 °C for 2 hrs. The reaction was quenched with water and then extracted with EtOAc. The combined organic layers were dried over magnesium sulfate and concentrated under reduced pressure. Flash column chromatography (1:2:17 EtOAc/CHCl₃/Hex) afforded compound **14** (118 mg, 95%) as a white crystalline solid: IR ν_{max} (KBr, cm⁻¹): 3070, 3003, 2955, 2931, 2897, 2858, 2830, 2360, 2341, 1619, 1594, 1509; ¹H NMR (400 MHz, CDCl₃) δ 7.44 (s, 1H), 6.98 (s, 1H), 6.92 (d, *J* = 7.8 Hz, 1H), 6.82 (d, *J* = 1.3 Hz, 1H), 6.79 (dd, *J* = 7.9, 1.6 Hz, 1H), 6.07 (d, *J* = 1.3 Hz, 1H), 6.04 (d, *J* = 1.2 Hz, 1H), 5.24 (s, 2H), 4.97 (s, 2H), 4.00 (s, 3H), 3.80 (s, 3H), 1.13 (s, 9H), 0.26 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 149.46, 148.68, 147.94, 146.94, 143.28, 136.76, 132.52, 129.88, 124.85, 123.44, 123.33, 123.18, 110.25, 108.67, 104.89, 101.95, 101.27, 73.73, 72.89, 56.00, 55.86, 26.06, 18.73, -3.18; HRMS-ESI calcd for C₂₇H₃₂O₆Si (M+Na)⁺ 503.18604, found 503.18721; mp 162–164 °C.

4.1.5.3. 9-(Benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-4-ol (15): A solution of **14** (0.075 g, 0.156 mmol) and TBAF (1 M in THF, 0.234 mL) in DCM (1.7 mL) was stirred at room temperature for 30 minutes. The reaction mixture was quenched with water and several drops of HCl (aq., 2M) before being extracted with DCM. The combined organic layers were washed with water, brine, and then dried over sodium sulfate and concentrated under reduced pressure. Flash column chromatography (2:1:17 EtOAc/EtOH/Hex) afforded compound **15** (53 mg, 93%) as an orange solid: IR ν_{max} (KBr, cm⁻¹): 3271, 3091, 3003, 2939, 2902, 2860, 2833, 2780, 1620, 1597, 1509; ¹H NMR (400 MHz, Acetone-d₆) δ 7.62 (s, 1H), 7.02 (s, 1H), 6.98 (d, *J* = 7.9 Hz, 1H), 6.87 (d, *J* = 1.7 Hz, 1H), 6.83 (dd, *J* = 7.9, 1.7 Hz, 1H), 6.09 (s, 1H), 6.07 (s, 1H), 5.18 (s, 2H), 4.92 (d, *J* = 12.4 Hz, 1H), 4.88 (d, *J* = 12.3 Hz, 1H), 3.93 (s, 3H), 3.71 (s, 3H); ¹³C NMR (75 MHz, Acetone-d₆) δ 150.74, 149.83, 148.83, 147.68, 145.16, 137.37, 133.52, 130.36, 123.99, 123.54, 121.29, 119.22, 110.89, 109.23, 105.65, 102.14, 101.99, 73.76, 72.26, 55.89, 55.68; HRMS-ESI calcd for C₂₁H₁₈O₆ (M+Na)⁺ 389.09956, found 389.09906.

4.1.5.4. 4-(Benzo[d][1,3]dioxol-5-yl)-9-hydroxy-6,7-dimethoxynaphtho[2,3-c]furan-1(3H)-one (16): A mixture of **14** (0.100 g, 0.208 mmol) and Cs₂CO₃ (0.068 g, 0.208 mmol) in DMF/H₂O (10:1, v/v, 0.229 mL) was stirred overnight at room temperature open to the air. The reaction was quenched with HCl (aq., 2M) and extracted with EtOAc. The combined organic layers were washed with HCl (aq., 2M), water, brine, and then dried over sodium sulfate. Flash column chromatography (25 → 30% EtOAc in Hex) then

afforded compound **16** (15 mg, 19%) as a pale yellow solid: ^1H NMR (400 MHz, Acetone- d_6) δ 9.02 (s, 1H), 7.67 (s, 1H), 7.14 (s, 1H), 7.03 (d, $J = 7.9$ Hz, 1H), 6.98 (d, $J = 1.5$ Hz, 1H), 6.94 (dd, $J = 7.9, 1.7$ Hz, 1H), 6.12 (s, 1H), 6.10 (s, 1H), 5.31 (d, $J = 14.7$ Hz, 1H), 5.26 (d, $J = 14.7$ Hz, 1H), 4.00 (s, 3H), 3.79 (s, 3H); ^{13}C NMR (101 MHz, Acetone- d_6) δ 173.22, 153.59, 153.17, 150.52, 149.20, 148.28, 138.24, 134.53, 130.90, 124.17, 119.96, 110.82, 109.60, 105.59, 104.22, 102.52, 102.36, 70.73, 56.11, 55.87; HRMS-ESI calcd for $\text{C}_{21}\text{H}_{16}\text{O}_7$ ($\text{M}+\text{Na}$) $^+$ 403.07882, found 403.07804.

4.1.5.5. (2S,3R,4S,5S)-2-((9-(Benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-1,3-dihydronaphtho[2,3-c]furan-4-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate

(17): Starting from 1,2,3,4-tetra-*O*-acetyl-L-arabinopyranose and following the general procedure for bromination/glycosylation replacing diphyllin with compound **15**, flash chromatography (3:6:11 EtOAc/ CHCl_3 /Hex \rightarrow 4:6:10 EtOAc/ CHCl_3 /Hex) afforded compound **17** (63 mg, 33%) as a white solid: $[\alpha]_D^{20} - 9.02^\circ$ (c 0.12, CHCl_3); IR ν_{max} (KBr, cm^{-1}): 3072, 3002, 2958, 2905, 2859, 2834, 2780, 2255, 1748, 1621, 1592, 1508; ^1H NMR (400 MHz, CDCl_3) δ 7.53 (s, 1H), 6.95 (s, 1H), 6.93 (d, $J = 7.8$ Hz, 1H), 6.79 (d, $J = 1.9$ Hz, 1H), 6.77 (dd, $J = 7.7, 1.9$ Hz, 1H), 6.07 (br s, 1H), 6.04 (br s, 1H), 5.68 (dd, $J = 9.6, 7.2$ Hz, 1H), 5.38 (br d, $J = 12.5$ Hz, 1H), 5.35 (br s, 1H), 5.29 (br d, $J = 12.4$ Hz, 1H), 5.14 (dd, $J = 9.7, 3.5$ Hz, 1H), 5.01 (d, $J = 7.1$ Hz, 1H), 4.97 (br d, $J = 13.9$ Hz, 1H), 4.93 (br d, $J = 12.8$ Hz, 1H), 4.16 (br d, $J = 13.1$, 1H), 4.04 (br s, 3H), 3.80 (br s, 3H), 3.69 (br d, $J = 13.1$ Hz, 1H), 2.21 (br s, 3H), 2.07 (br s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 170.45, 170.30, 169.75, 149.84, 149.36, 147.99, 147.12, 144.63, 136.73, 131.99, 129.73, 127.28, 123.29, 123.04, 122.93, 122.70, 110.03, 109.95, 108.78, 108.76, 104.59, 101.50, 101.36, 73.29, 72.41, 70.46, 69.56, 67.62, 64.10, 56.16, 55.86, 21.12, 20.85; HRMS-ESI calcd for $\text{C}_{32}\text{H}_{32}\text{O}_{13}$ ($\text{M}+\text{Na}$) $^+$ 647.17351, found 647.17458; mp 117–119.5 $^\circ\text{C}$.

4.1.5.6. (2S,3R,4S,5S)-2-((9-(Benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-3-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate

(18): Starting from 1,2,3,4-tetra-*O*-acetyl-L-arabinopyranose and following the general procedure for bromination/glycosylation replacing diphyllin with compound **16**, flash chromatography (0.75% MeOH in CHCl_3) afforded compound **18** (20 mg, 80%) as a pale-orange solid: $[\alpha]_D^{20} - 18.8^\circ$ (c 0.09, CHCl_3); IR ν_{max} (KBr, cm^{-1}): 3073, 3005, 2958, 2936, 2835, 2780, 2256, 1749, 1619, 1598, 1507; ^1H NMR (400 MHz, CDCl_3) δ 7.85 (s, 1H), 6.96 (dd, $J = 8.0, 2.2$ Hz, 1H), 6.93 (s, 1H), 6.80–6.75 (m, 2H), 6.22 (d, $J = 7.3$ Hz, 1H), 6.09 (br s, 1H), 6.06 (br s, 1H), 5.70 (dd, $J = 9.8, 7.3$ Hz, 1H), 5.36 (br s, 1H), 5.27 (dd, $J = 9.9, 3.6$ Hz, 1H), 5.15 (br d, $J = 15.2$ Hz, 1H), 5.10 (br d, $J = 15.0$ Hz, 1H), 4.10 (s, 3H), 4.09–4.01 (m, 2H), 3.86 (br s, 1H), 3.83 (s, 3H), 2.16 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 170.39, 170.35, 170.12, 169.54, 152.61, 149.90, 149.46, 148.41, 148.39, 147.69, 138.60, 133.55, 129.61, 127.16, 123.84, 123.03, 109.83, 109.18, 109.15, 108.52, 103.77, 101.56, 101.33, 70.23, 69.92, 69.01, 67.99, 64.46, 56.32, 56.03, 21.10, 21.09, 20.83; HRMS-ESI calcd for $\text{C}_{32}\text{H}_{30}\text{O}_{14}$ ($\text{M}+\text{Na}$) $^+$ 661.15278, found 661.15392; mp 112–114.5 $^\circ\text{C}$.

4.2. Biology

4.2.1. HT-29 cell proliferation assay—The cytotoxicity of compounds **6a–c**, **7a–c**, **12**, and **17–18** was screened against HT-29 cell lines using the previously reported protocol.⁶³

4.2.2. HT-29 and OVCAR3 cell proliferation assays—The cytotoxicity of the tested compounds was screened against HT-29 (compounds **8a–b**, **9a–b**, **10–11**, and **13**) and OVCAR3 cell lines using the following protocol:

4.2.2.1 Cell Culture: Ovarian cancer cell line, OVCAR3, and colon cancer cell line, HT-29, were purchased from the American Type Culture Collection. OVCAR3 cells were grown in RPMI 1640 medium supplemented with 20% fetal bovine serum (FBS), 1% penicillin/streptomycin (P/S), and 10 µg/mL insulin. HT-29 cells were grown in RPMI 1640 with 10% FBS and 1% P/S. Cultured cells were maintained in a humidified incubator at 37°C in 5% CO₂. Cells were passaged a maximum of 20 times after resuscitation from frozen stocks. Cell lines were validated by STR in 2015 and 2017 and tested *mycoplasma* free in 2017.

4.2.2.2 Cell Viability Assay: Cells were seeded in 96-well, clear, flat-bottomed plates at 2,500 to 5,000 cells per well, depending on the cell line, and allowed to attach overnight. Compounds suspended in DMSO were diluted to final concentrations as noted in figures in the appropriate media and added to the cells. The final vehicle concentration was 0.25% to achieve the widest dose range possible. Cells were incubated for 24, 48, or 72 hours. The amount of cellular protein content attached to the plate bottom after fixation at the end of the treatment period was dyed and measured as previously described with sulforhodamine B (SRB) assay as a measure of cell survival.⁶⁴ Treatment measurements were normalized to vehicle, and dose response curves with corresponding IC₅₀ values were generated using Graphpad Prism Software.

4.2.3. K562 and K/VP.5 cell proliferation assays—A cell proliferation assay⁶⁵ was performed by using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), the CellTiter 96® AQueous One Solution Reagent (Promega, Madison, WI) which measures the ability of viable cells to enzymatically reduce MTS. DMSO used as control or various concentrations of phyllanthusmin analogs dissolved in DMSO were added to one ml cell suspensions (7.5×10^4 cell/ml) of K562 and K/VP.5 cells (final DMSO concentration 0.5%) followed by addition of triplicate 0.1 ml aliquots from these cell suspensions to 96 well plates. After 72 hr incubation at 37°C, 6 µL of MTS reagent was added to each well followed by incubation for 1 hr at 37°C. Reduced MTS was measured by absorbance at 490 nm using a Synergy^{H1} Hybrid Reader (Biotek, Winooski, Vermont). The IC₅₀ values for growth inhibition were determined using a logistic four parameter fit of concentration versus absorbance curves (Sigma Plot, Systat Software Inc. San Jose, CA, USA).

4.2.4. Topoisomerase II α -catalyzed plasmid DNA relaxation—Reaction mixtures (20 µL) contained 125 ng of topoisomerase II α , isolated as previously described,⁶⁶ 150 ng of negatively supercoiled pBR322 DNA, 1 mM ATP in assay buffer [10 mM Tris-HCl, 50 mM KCl, 50 mM NaCl, 0.1 mM Na₂EDTA, 5 mM MgCl₂, 2.5% (v/v) glycerol, pH 8.0, and

1 μL of DMSO control, etoposide, phyllanthusmins, or diphyllin (all drugs in DMSO solvent). Components of the assay mixture were assembled and mixed on ice prior to addition of drugs/DMSO. Reactions were initiated by addition of enzyme and experimental mixtures were then incubated at 37°C for 15 min. DNA relaxation was quenched by addition of 2 μL of a stop solution (0.77% SDS, 77 mM Na_2EDTA). 4 μL of $10\times$ DNA loading solution (Invitrogen) at 45°C was added to the mixture and incubated for 2 min. DNA bands were separated by electrophoresis (50 V for 10 min then overnight at 15 V) on a TBE agarose gel [1% (w/v)]. The agarose gel was then stained with ethidium bromide (2 $\mu\text{g}/\text{ml}$) for 30 min. DNA bands were visualized under UV light on a Molecular Imager (ChemiDoc™ XRS, Bio-Rad). Conversion from supercoiled pBR322 DNA to relaxed topoisomer bands was monitored as a readout of enzyme activity or its inhibition by tested agents.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Institutes of Health [grant 2P01 CA125066 (to ADK)] and predoctoral fellowships from the NIH/OSU Chemistry-Biology Interface Training Program [GM08512 (to JLW)], the American Foundation for Pharmaceutical Education (to JLW), and an OSU University Fellowship (to ACH).

References and notes

1. Qi W, Hua L, Gao K. Chemical constituents of the plants from the genus phyllanthus. *Chem Biodivers.* 2014; 11:364–395. [PubMed: 24634068]
2. Ren Y, Lantvit DD, Deng Y, Kanagasabai R, Gallucci JC, Ninh TN, Chai H-B, Soejarto DD, Fuchs JR, Yalowich JC, Yu J, Swanson SM, Kinghorn AD. Potent cytotoxic aryl-naphthalene lignan lactones from *Phyllanthus poilanei*. *J Nat Prod.* 2014; 77:1494–1504. [PubMed: 24937209]
3. Wu S-J, Wu T-S. Cytotoxic aryl-naphthalene lignans from *Phyllanthus oligospermus*. *Chem Pharm Bull (Tokyo).* 2006; 54:1223–1225. [PubMed: 16880677]
4. Murakami T, Matsushima A. Studies on the constituents of Japanese Podophyllaceae plants. I. On the constituent of the root of *Diphylleia grayi*. *J Pharm Soc Jpn.* 1961; 81:1596.
5. Day S-H, Lin Y-C, Tsai M-L, Tsao L-T, Ko H-H, Chung M-I, Lee J-C, Wang J-P, Won S-J, Lin C-N. Potent cytotoxic lignans from *Justicia procumbens* and their effects on nitric oxide and tumor necrosis factor- α production in mouse macrophages. *J Nat Prod.* 2002; 65:379–381. [PubMed: 11908984]
6. Fukamiya N, Lee K-H. Antitumor agents, 81. Justicidin-A and diphyllin, two cytotoxic principles from *Justicia procumbens*. *J Nat Prod.* 1986; 49:348–350. [PubMed: 3734816]
7. Di Giorgio C, Delmas F, Akhmedjanova V, Ollivier E, Bessonova I, Riad E, Timon-David P. *In vitro* antileishmanial activity of diphyllin isolated from *Haplophyllum bucharicum*. *Planta Med.* 2005; 71:366–369. [PubMed: 15856417]
8. Asano J, Chiba K, Tada M, Yoshii T. Antiviral activity of lignans and their glycosides from *Justicia procumbens*. *Phytochemistry.* 1996; 42:713–717. [PubMed: 8768323]
9. Susplugas S, Hung NV, Bignon J, Thoison O, Kruczynski A, Sévenet T, Guéritte F. Cytotoxic aryl-naphthalene lignans from a Vietnamese acanthaceae *Justicia patentiiflora*. *J Nat Prod.* 2005; 68:734–738. [PubMed: 15921419]
10. Zhang Y-J, Litaudon M, Bousserouel H, Martin M-T, Thoison O, Léonce S, Dumontet V, Sévenet T, Guéritte F. Sesquiterpenoids and cytotoxic lignans from the bark of *Libocedrus chevalieri*. *J Nat Prod.* 2007; 70:1368–1370. [PubMed: 17676899]

11. Tuchinda P, Kumkao A, Pohmakotr M, Sophasan S, Santisuk T, Reutrakul V. Cytotoxic aryl-naphthalide lignan glycosides from the aerial parts of *Phyllanthus taxodiifolius*. *Planta Med.* 2006; 72:60–62. [PubMed: 16450297]
12. Shi D-K, Zhang W, Ding N, Li M, Li Y-X. Design, Synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors. *Eur J Med Chem.* 2012; 47:424–431. [PubMed: 22119124]
13. Ikeda R, Nagao T, Okabe H, Nakano Y, Matsunaga H, Katano M, Mori M. Antiproliferative constituents in umbelliferae plants. IV. Constituents in the fruits of *Anthriscus sylvestris* HOFFM. *Chem Pharm Bull.* 1998; 46:875–878. [PubMed: 9621423]
14. Yang X-W, He H-P, Du Z-Z, Liu H-Y, Di Y-T, Ma Y-L, Wang F, Lin H, Zuo Y-Q, Li L, Hao X-J. Tarennanosides A–H, eight new lignan glucosides from *Tarenna attenuata* and their protective effect on H₂O₂-induced impairment in PC12 cells. *Chem Biodivers.* 2009; 6:540–550. [PubMed: 19353535]
15. Zheng C-J, Huang B-K, Han T, Zhang Q-Y, Zhang H, Rahman K, Qin L-P. Nitric oxide scavenging lignans from *Vitex negundo* seeds. *J Nat Prod.* 2009; 72:1627–1630. [PubMed: 19715321]
16. Charlton JL. Antiviral activity of lignans. *J Nat Prod.* 1998; 61:1447–1451. [PubMed: 9834179]
17. Hara H, Fujihashi T, Sakata T, Kaji A, Kaji H. Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents. *AIDS Res Hum Retroviruses.* 1997; 13:695–705. [PubMed: 9168238]
18. Janmanchi D, Tseng YP, Wang K-C, Huang RL, Lin CH, Yeh SF. Synthesis and the biological evaluation of aryl-naphthalene lignans as anti-hepatitis B virus agents. *Bioorg Med Chem.* 2010; 18:1213–1226. [PubMed: 20061158]
19. Prieto JM, Recio MC, Giner RM, Máñez S, Massmanian A, Waterman PG, Ríos JL. Topical anti-inflammatory lignans from *Haplophyllum hispanicum*. *Z Für Naturforschung C.* 1996; 51:618–622.
20. Chen C-C, Hsin W-C, Ko F-N, Huang Y-L, Ou J-C, Teng C-M. Antiplatelet aryl-naphthalide lignans from *Justicia procumbens*. *J Nat Prod.* 1996; 59:1149–1150. [PubMed: 8988600]
21. Leung Y-M, Tsou Y-H, Kuo C-S, Lin S-Y, Wu P-Y, Hour M-J, Kuo Y-H. Aryl-naphthalene lignans from *Taiwania cryptomerioides* as novel blockers of voltage-gated K⁺ channels. *Phytomedicine.* 2010; 18:46–51. [PubMed: 20684875]
22. Xu H, Zhang X, Tian X, Lu M, Wang Y. Synthesis and insecticidal activity of novel 4β-Halogenated benzoylamino podophyllotoxins against *Pieris rapae* LINNAEUS. *Chem Pharm Bull (Tokyo).* 2002; 50:399–402. [PubMed: 11911206]
23. Loers G, Yashunsky DV, Nifantiev NE, Schachner M. Neural cell activation by phenolic compounds from the siberian larch (*Larix sibirica*). *J Nat Prod.* 2014; 77:1554–1561. [PubMed: 24963869]
24. Pommier Y. Drugging topoisomerases: lessons and challenges. *ACS Chem Biol.* 2013; 8:82–95. [PubMed: 23259582]
25. Kang K, Oh SH, Yun JH, Jho EH, Kang J-H, Batsuren D, Tunsag J, Park KH, Kim M, Nho CW. A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide. *Neoplasia N Y N.* 2011; 13:1043–1057.
26. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. *Clin Pharmacokinet.* 1987; 12(4):223–252. [PubMed: 3297462]
27. Phillippe M, Dechaux E, Monneret C, Bertounesque E. Etoposide: discovery and medicinal chemistry. *Curr Med Chem.* 2004; 11:2443–2466. [PubMed: 15379707]
28. Zhao Y, Ni C, Zhang Y, Zhu L. Synthesis and bioevaluation of diphyllin glycosides as novel anticancer agents. *Arch Pharm (Weinheim).* 2012; 345:622–628. [PubMed: 22592997]
29. Gui M, Shi D-K, Huang M, Zhao Y, Sun Q-M, Zhang J, Chen Q, Feng J-M, Liu C-H, Li M, Li Y-X, Geng M, Ding J. D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase II α . *Invest New Drugs.* 2011; 29:800–810. [PubMed: 20336347]
30. Govindachari TR, Sathe SS, Viswanathan N, Pai BR, Srinivasan M. Chemical constituents of *Cleistanthus collinus*. *Tetrahedron.* 1969; 25:2815–2821.
31. Lakshmi TG, Srimannarayana G, Rao NVS. A new glucoside from *Cleistanthus collinus*. *Curr Sci.* 1970; 39:395–396.

32. Meenakshi J, Shanmugam G. Cleistanthin A, a diphyllin glycoside from *Cleistanthus collinus* is cytotoxic to PHA-stimulated (proliferating) human lymphocytes. *Drug Dev Res.* 2000; 51:187–190.
33. Parasuraman S, Raveendran R, Rajesh NG, Nandhakumar S. Sub-chronic toxicological evaluation of cleistanthin A and cleistanthin B from the leaves of *Cleistanthus collinus* (Roxb.). *Toxicol Rep.* 2014; 1:596–611. [PubMed: 28962273]
34. Pradheepkumar CP, Panneerselvam N, Shanmugam G. Cleistanthin A causes DNA strand breaks and induces apoptosis in cultured cells. *Mutat Res.* 2000; 464:185–193. [PubMed: 10648905]
35. Kumar CPP, Panneerselvam N, Rajesh S, Shanmugam G. Cytotoxic and genotoxic effects of cleistanthin B in normal and tumour cells. *Mutagenesis.* 1996; 11:553–557. [PubMed: 8962424]
36. Kumar CP, Pande G, Shanmugam G. Cleistanthin B causes G1 arrest and induces apoptosis in mammalian cells. *Apoptosis.* 1998; 3:413–419. [PubMed: 14646474]
37. Thummar VR, Parasuraman S, Basu D, Raveendran R. Evaluation of in vivo antitumor activity of cleistanthin B in swiss albino mice. *J Tradit Complement Med.* 2016; 6:383–388. [PubMed: 27774423]
38. Tuchinda P, Kornsakulkarn J, Pohmakotr M, Kongsaree P, Prabpai S, Yoosook C, Kasisit J, Napaswad C, Sophasan S, Reutrakul V. Dichapetalin-type triterpenoids and lignans from the aerial parts of *Phyllanthus acutissima*. *J Nat Prod.* 2008; 71:655–663. [PubMed: 18271551]
39. Ren Y, Yuan C, Deng Y, Kanagasabai R, Ninh TN, Tu VT, Chai H-B, Soejarto DD, Fuchs JR, Yalowich JC, Yu J, Kinghorn AD. Cytotoxic and natural killer cell stimulatory constituents of *Phyllanthus songboiensis*. *Phytochemistry.* 2015; 111:132–140. [PubMed: 25596805]
40. Sastry K, Rao E. Isolation and structure of cleistanthoside A. *Planta Med.* 1983; 47:227–229. [PubMed: 17404921]
41. Himakoun L, Tuchinda P, Puchadapirom P, Tammasakchai R, Leardkamolkarn V. Evaluation of genotoxic and anti-mutagenic properties of cleistanthin A and cleistanthoside A tetraacetate. *Asian Pac J Cancer Prev.* 2011; 12:3271–3275. [PubMed: 22471465]
42. Wanitchakool P, Jariyawat S, Suksen K, Soorukram D, Tuchinda P, Piyachaturawat P. Cleistanthoside A tetraacetate-induced DNA damage leading to cell cycle arrest and apoptosis with the involvement of P53 in lung cancer cells. *Eur J Pharmacol.* 2012; 696:35–42. [PubMed: 23041153]
43. Puchadapirom P, Himakhun W, Tuchinda P, Himakoun L, Koomsang T, Suwannalert P. The effects of cleistanthoside A tetraacetate synthesis on acute toxicity and bone marrow micronucleus in ICR mice. *Walailak J Sci Technol WJST.* 2015; 12:605–611.
44. Naresh G, Kant R, Narender T. Silver(I)-catalyzed regioselective construction of highly substituted α -naphthols and its application toward expeditious synthesis of lignan natural products. *Org Lett.* 2015; 17:3446–3449. [PubMed: 26158760]
45. Kim HY, Oh K. A facile access to 4-substituted-2-naphthols via a tandem friedel–crafts reaction: a β -chlorovinyl ketone pathway. *Org Lett.* 2014; 16:5934–5936. [PubMed: 25356858]
46. Kocsis LS, Brummond KM. Intramolecular dehydro-Diels-Alder reaction affords selective entry to aryl-naphthalene or aryl-dihydronaphthalene lignans. *Org Lett.* 2014; 16:4158–4161. [PubMed: 25061845]
47. Gao P, Liu J, Wei Y. Hypervalent iodine(III)-mediated benzannulation of enamines with alkynes for the synthesis of polysubstituted naphthalene derivatives. *Org Lett.* 2013; 15:2872–2875. [PubMed: 23675948]
48. Jiang H, Cheng Y, Zhang Y, Yu S. *De novo* synthesis of polysubstituted naphthols and furans using photoredox neutral coupling of alkynes with 2-bromo-1,3-dicarbonyl compounds. *Org Lett.* 2013; 15:4884–4887. [PubMed: 24000895]
49. Patel RM, Argade NP. Palladium-promoted [2 + 2 + 2] cocyclization of arynes and unsymmetrical conjugated dienes: synthesis of justicidin B and retrojusticidin B. *Org Lett.* 2013; 15:14–17. [PubMed: 23237050]
50. Peng S, Wang L, Wang J. Direct access to highly substituted 1-naphthols through palladium-catalyzed oxidative annulation of benzoylacetates and internal alkynes. *Chem – Eur J.* 2013; 19:13322–13327. [PubMed: 24078414]

51. Yamamoto Y, Mori S, Shibuya M. A combined transition-metal-catalyzed and photopromoted process: synthesis of 2,3-fused 4-phenylnaphthalen-1-yl carboxylates from 1,7-diaryl-1,6-diyne. *Chem - Eur J*. 2015; 21:9093–9100. [PubMed: 25980465]
52. Charlton JL, Oleschuk CJ, Chee G-L. Hindered rotation in aryl-naphthalene lignans. *J Org Chem*. 1996; 61:3452–3457.
53. Hui J, Zhao Y, Zhu L. Synthesis and in vitro anticancer activities of novel aryl-naphthalene lignans. *Med Chem Res*. 2012; 21:3994–4001.
54. Wang Y, Xia C, Zhang W, Zhao Y. Synthesis and biological evaluation of novel lignan glycosides as anticancer agents. *Chem Biol Drug Des*. 2016; 88:562–567. [PubMed: 27160642]
55. Liu L, Hu Y, Liu H, Liu D-Y, Xia J-H, Sun J-S. First Total Synthesis of the bioactive aryl-naphthyl lignan 4-*O*-glycosides phyllanthusmin D and 4'-*O*-acetylmananthoside B. *Eur. J. Org. Chem*. 2017:3674–3680.
56. Arnold BJ, Mellows SM, Sammes PG. Photochemical Reactions. Part I. A New Route to Tetradehydropodophyllotoxin, Taiwanin E, Related Compounds. *J Chem Soc [Perkin 1]*. 1973
57. Singh, O., Tapadiya, S., Deshmukh, R. Process for the Synthesis of Cleistanthin. WO. 2010089778 (A2). Aug 12, 2010
58. Sakai N, Moriya T, Konakahara T. An Efficient One-Pot Synthesis of Unsymmetrical Ethers: A Directly Reductive Deoxygenation of Esters Using an InBr₃/Et₃SiH Catalytic System. *J Org Chem*. 2007; 72:5920–5922. [PubMed: 17602594]
59. Ohta K, Munakata K. Justicidin C and D, the 1-methoxy-2,3-naphthalide lignans, isolated from *Justicia procumbens* L. *Tetrahedron Lett*. 1970; 11:923–925.
60. Mondal S, Maji M, Basak A. A Garratt-Braverman route to aryl naphthalene lignans. *Tetrahedron Lett*. 2011; 52:1183–1186.
61. Ritke MK, Yalowich JC. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. *Biochem Pharmacol*. 1993; 46:2007–2020. [PubMed: 8267650]
62. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K562 cells. *Br J Cancer*. 1994; 69(4):687–697. [PubMed: 8142256]
63. Ren Y, Matthew S, Lantvit DD, Ninh TN, Chai H, Fuchs JR, Soejarto DD, de Blanco EJC, Swanson SM, Kinghorn AD. Cytotoxic and NF- κ B inhibitory constituents of the stems of *Cratogeomys cochinchinense* and their semisynthetic analogues. *J Nat Prod*. 2011; 74:1117–1125. [PubMed: 21428375]
64. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat Protoc*. 2006; 1:1112–1116. [PubMed: 17406391]
65. Hasinoff BB, Wu X, Patel D, Kanagasabai R, Karmahapatra S, Yalowich JC. Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisomerase II α isoform. *J Pharmacol Exp Ther*. 2016; 356:397–409. [PubMed: 26660439]
66. Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, Yalowich JC. Biochemical and proteomics approaches to characterize topoisomerase II α cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase II α . *Mol Pharmacol*. 2005; 67:937–947. [PubMed: 15602006]




Figure 1. Phyllanthusmins A–E along with structurally related arlynaphthalene lignan lactones (A) and aryletralin lignan lactones (B).




Figure 2.
Chemical structures of compounds 7–11.






Figure 3. DNA topoisomerase II α mediated pBR322 DNA relaxation in the absence or presence of etoposide, diphyllin, or PHY analogue.



Scheme 1.
Synthesis of diphyllin glycoside analogues **6a–c** possessing an arabinose ring.



Scheme 2.
Preparation of C-ring lactone analogues **12**, **13**, **17**, and **18**.

Table 1

Phyllanthusmin analogues and corresponding antiproliferative data in HT-29 and OVCAR3 cell lines expressed as IC₅₀ values in μM .

| Cmpd | Carbohydrate | HT-29 | OVCAR3 |
|------------------|---------------------|--------------|---------------|
| 6a | L-arabinose (-OAc) | 0.14 | 0.29 |
| 6b | L-arabinose (-OH) | 3.2 | 4.8 |
| 6c | L-arabinose (-OMe) | 0.13 | 0.81 |
| 7a | D-xylose (-OAc) | 0.16 | 0.57 |
| 7b | D-xylose (-OH) | 1.4 | 0.69 |
| 7c | D-xylose (-OMe) | 0.018 | 7.6 |
| 8a | D-glucose (-OAc) | 0.043 | >10 |
| 8b | D-glucose (-OH) | 4.8 | >10 |
| 9a | D-galactose (-OAc) | 0.044 | 0.36 |
| 9b | D-galactose (-OH) | >10 | >10 |
| 10 | D-arabinose (-OAc) | 0.046 | 0.37 |
| 11 | Lactose (-OAc) | 2.0 | >10 |
| 12 | D-xylose (-OMe) | 1.7 | 0.45 |
| 13 | L-arabinose (-OAc) | >10 | >10 |
| 17 | L-arabinose (-OAc) | 1.4 | >10 |
| 18 | L-arabinose (-OAc) | 0.47 | >10 |
| Taxol | | 0.011 | 0.011 |
| Etoposide | | 15 | 2.9 |

Table 2

Antiproliferative data (IC₅₀, μM) for PHY analogues in etoposide sensitive K562 cells and isogenic etoposide resistant K/VP.5 cells, where “n” is the number of replicate experiments performed on separate days.

| Compound | K562 | K/VP.5 | Relative Resistance ^a | n |
|-----------|-----------------|-----------------|----------------------------------|---|
| etoposide | 1.22 | 35.36 | 28.98 | 1 |
| 8a | 0.72 \pm 0.10 | 0.69 \pm 0.05 | 0.96 | 3 |
| 6a | 0.85 \pm 0.09 | 0.92 \pm 0.13 | 1.08 | 4 |
| 6c | 1.26 \pm 0.2 | 1.28 \pm 0.44 | 1.02 | 4 |
| 7c | 0.47 \pm 0.06 | 0.43 \pm 0.09 | 0.91 | 6 |
| diphyllin | 2.38 \pm 0.37 | 2.31 \pm 0.35 | 0.97 | 3 |

^aRelative resistance is calculated by the ratio of IC₅₀ values in K/VP.5 compared to K562 cells.